On June 18, 2019, we established the cell therapy center in China Medical University Hospital to promote clinical services related to the Regulations of special Medical Techniques, and actively develop and launch a number of multi-center clinical trials related to cell therapy.

Including DC, CIK, DC-CIK, GDT, DC-CIK WT1 and other cells.

Approved by the Ministry of Health and Welfare, they are used to treat a variety of cancers in the first to fourth stages, with the highest number of items in Taiwan (8 items). As of July 31, 2022, DC has received a total of 172 cases, and DC-CIK has a total of 172 cases, both ranking first in the country.

For the hose patients with staged IV cancer receiving DC therapy had 1-years and 2-years survival rate as 49.6% and 32.4% respectively.

One-year and 2-year survival rate for patients receiving DC-CIK therapy were 63.8% and 44.3% respectively. Immune cell therapy offers a first-line chance for terminal cancer patients.